Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FENC Adherex Technologies	$8.44 -3.5%	$8.09	$3.96 ▼ $9.30	$233.08M	0.39	92,467 shs	60,846 shs
GNFT GENFIT	$3.82 -0.4%	$4.04	$2.55 ▼ $6.42	$189.51M	1.08	10,314 shs	603 shs
GRNA GreenLight Biosciences	$0.30	$0.30	$0.18 ▼ $5.90	$45.43M	1.44	486,986 shs	732 shs
IPHA Innate Pharma	$1.92 +8.5%	$1.96	$1.29 ▼ $3.51	$176.98M	0.21	187,954 shs	17,431 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FENC Adherex Technologies	0.00%	-3.87%	+7.38%	+66.14%	+26.92%
GNFT GENFIT	0.00%	+4.52%	-5.00%	+9.47%	-17.60%
GRNA GreenLight Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%
IPHA Innate Pharma	0.00%	+10.14%	+1.05%	-2.54%	-12.73%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FENC Adherex Technologies	2.3213 of 5 stars	3.6	1.0	0.0	0.0	2.1	3.3	0.0
GNFT GENFIT	2.2957 of 5 stars	3.5	5.0	0.0	0.0	0.0	0.0	0.0
GRNA GreenLight Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IPHA Innate Pharma	1.8724 of 5 stars	3.8	3.0	0.0	0.0	0.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FENC Adherex Technologies	3.25	Buy	$13.00	54.03% Upside
GNFT GENFIT	3.00	Buy	$13.00	240.76% Upside
GRNA GreenLight Biosciences	0.00	N/A	N/A	N/A
IPHA Innate Pharma	3.50	Strong Buy	$11.00	472.92% Upside

Current Analyst Ratings Breakdown

Latest GRNA, GNFT, IPHA, and FENC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/20/2025	FENC Adherex Technologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
5/14/2025	FENC Adherex Technologies	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $13.00
4/24/2025	IPHA Innate Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.50 ➝ $11.00

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FENC Adherex Technologies	$47.54M	4.90	$0.03 per share	261.49	($0.21) per share	-40.19
GNFT GENFIT	$76.77M	2.48	$0.07 per share	54.19	$1.50 per share	2.54
GRNA GreenLight Biosciences	$10.20M	4.45	N/A	N/A	$0.32 per share	0.94
IPHA Innate Pharma	$12.62M	14.02	N/A	N/A	$0.11 per share	17.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FENC Adherex Technologies	-$440K	-$0.51	N/A	N/A	N/A	-45.52%	N/A	-26.37%	8/12/2025 (Estimated)
GNFT GENFIT	$1.63M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/24/2025 (Estimated)
GRNA GreenLight Biosciences	-$167.05M	-$1.14	N/A	∞	N/A	-1,521.00%	-374.26%	-122.78%	N/A
IPHA Innate Pharma	-$53.53M	N/A	0.00	∞	N/A	N/A	N/A	N/A	9/17/2025 (Estimated)

Latest GRNA, GNFT, IPHA, and FENC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	FENC Adherex Technologies	-$0.06	N/A	N/A	N/A	$9.52 million	N/A
5/13/2025	Q1 2025	FENC Adherex Technologies	-$0.12	-$0.04	+$0.08	-$0.04	$8.18 million	$8.51 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FENC Adherex Technologies	N/A	N/A	N/A	N/A	N/A
GNFT GENFIT	N/A	N/A	N/A	N/A	N/A
GRNA GreenLight Biosciences	N/A	N/A	N/A	N/A	N/A
IPHA Innate Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FENC Adherex Technologies	N/A	5.13	4.97
GNFT GENFIT	0.08	1.23	1.23
GRNA GreenLight Biosciences	0.49	1.21	1.21
IPHA Innate Pharma	2.52	2.60	2.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FENC Adherex Technologies	55.51%
GNFT GENFIT	2.24%
GRNA GreenLight Biosciences	24.41%
IPHA Innate Pharma	0.16%

Insider Ownership

Company	Insider Ownership
FENC Adherex Technologies	11.76%
GNFT GENFIT	4.20%
GRNA GreenLight Biosciences	30.30%
IPHA Innate Pharma	31.89%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FENC Adherex Technologies	10	27.60 million	24.35 million	Optionable
GNFT GENFIT	120	50.00 million	47.90 million	Not Optionable
GRNA GreenLight Biosciences	280	151.68 million	105.72 million	Not Optionable
IPHA Innate Pharma	220	92.18 million	62.78 million	Not Optionable

GRNA, GNFT, IPHA, and FENC Headlines

Recent News About These Companies

Innate Pharma (NASDAQ:IPHA) Trading 1.7% Higher - What's Next?

July 17 at 3:04 AM | marketbeat.com

IPHA Innate Pharma S.A. - Seeking Alpha

July 2, 2025 | seekingalpha.com

Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences

June 17, 2025 | businesswire.com

Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress

June 13, 2025 | businesswire.com

Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences

May 27, 2025 | businesswire.com

ASCO: Innate claims long-term lymphoma data show 'sustained effect' of anti-KIR3DL2 antibody

May 23, 2025 | fiercebiotech.comF

Outcome of Innate Pharma’s 2025 Annual General Meeting

May 23, 2025 | finance.yahoo.com

Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides

May 23, 2025 | businesswire.com

Outcome of Innate Pharma's 2025 Annual General Meeting

May 23, 2025 | businesswire.com

Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting

May 19, 2025 | businesswire.com

Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress

May 15, 2025 | businesswire.com

Innate Pharma S.A. (IPHA) Q1 2025 Earnings Call Transcript

May 13, 2025 | seekingalpha.com

Innate Pharma Reports First Quarter 2025 Business Update and Financial Results

May 13, 2025 | businesswire.com

Innate Pharma announces conference call and webcast for Q1 2025 business update

May 6, 2025 | businesswire.com

Innate Pharma Files Its 2024 Universal Registration Document (Document d'enregistrement universel) and 2024 Annual Report on Form 20-F

April 30, 2025 | businesswire.com

Innate Pharma Unveils Promising Preclinical Data for IPH4502 at AACR 2025

April 29, 2025 | tipranks.com

Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting

April 29, 2025 | businesswire.com

Innate Pharma price target lowered to $11 from $11.50 at H.C. Wainwright

April 25, 2025 | markets.businessinsider.com

Innate Pharma Announces €15M Investment by Sanofi

April 24, 2025 | businesswire.com

Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi's Intention to Make a Strategic Investment in the Company

April 23, 2025 | businesswire.com

Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition

April 16, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRNA, GNFT, IPHA, and FENC Company Descriptions

Adherex Technologies NASDAQ:FENC

$8.44 -0.31 (-3.54%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$8.44 0.00 (0.00%)

As of 07/18/2025 04:04 PM Eastern

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

GENFIT NASDAQ:GNFT

$3.82 -0.02 (-0.39%)

As of 07/18/2025 03:58 PM Eastern

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

GreenLight Biosciences NASDAQ:GRNA

FUNR manufactures and sells all-natural juice beverages. Its products include pomegranate cranberry, wild berry and passion fruit-orange. The company was founded by Alex C. Procopio on July 22, 1980 and is headquartered in Las Vegas, NV.

Innate Pharma NASDAQ:IPHA

$1.94 +0.16 (+9.30%)

As of 07/18/2025 03:57 PM Eastern

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time